BOCA RATON, Fla., Jan. 30, 2012 (GLOBE NEWSWIRE) -- Computer Vision Systems Laboratories Corp. (OTCBB:CVSL), announced today that its Chairman and CEO, Thomas DiCicco, was interviewed by TheStockRadio.com.
In the interview Mr. DiCicco discusses CVSL's growth strategy. In addition, Mr. DiCicco discusses CVSL's core business, the Sentinel BreastScan™, and its significant growth in the telecom sector since FY 2010.
The interview can be viewed at http://thestockradio.com
Thomas DiCicco, Chairman and CEO of Computer Vision Systems Labs, stated, "Being asked by 'The Stock Radio' to do the interview once again proves that there is real growing interest in our company and our products. We felt that this interview is one of several steps we are taking to get our story out to current and potential investors. We are seeing positive signs that the 2012 business environment is going to improve and support our growth plan."
About TheStockRadio.com
The StockRadio.com is a small-cap research and investment commentary provider. TheStockRadio.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. They provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on TheStockRadio please visit http://thestockradio.com
TheStockRadio.com Disclosure
TheStockRadio.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. TheStockRadio.com is a Web site wholly owned by Allan James Group. TheStockRadio.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, TheStockRadio.com, for complete risks and disclosures.
About the Maneuverable Guidewire
This guidewire (US Patent 7,141,024 Nov 28, 2006) is unique, easy to use, and intended for use in all PTCA procedures. The maneuverable-coiled guidewire is based on the "Buckling" theory in which the tip is bent according to the force applied to it. It is made of a high-grade stainless steel PTFE (Teflon) coated coil and a thin wire disposed in it. The distal end of the coil is treated in such a way that when the inner wire is pulled the distal tip buckles and bends accordingly. This feature is designed to allow the doctor to easily maneuver through the most tortuous vessels. CVSL plans to aggressively seek strategic partners through licensing agreements and joint ventures to manufacture and/or distribute the guidewire.
About the Sentinel BreastScan™
The Sentinel BreastScan is an advanced non-invasive infrared breast imaging system used as an adjunctive modality by doctors specializing in breast imaging and breast cancer treatment. The system helps fill the void in modalities that can especially benefit young women.
Utilizing infrared imaging and proprietary software employing artificial intelligence techniques, Sentinel BreastScan™ is designed to be used as an adjunctive test with mammography, ultrasound or clinical examination for the early detection of breast cancer. It is an FDA- 510k cleared, non-invasive touchless procedure offered to women of any age, to help determine current breast health. Test results are immediately available in the form of a fully interpreted, objective report, to assist in the doctor's determination of breast health.
The Sentinel BreastScan's ease of use and proprietary software provides the doctor with physiological breast data, which can provide very early, indirect indications of areas of concern, as well as pinpointing the location of anomalies. This differs from the anatomical data provided by mammography, ultrasound or MRI, which require that any anomaly be sufficiently developed to be physically detectable.
The Sentinel BreastScan™ is also a beneficial early detection method for young women of the age where detection is typically limited to palpation through self breast exams (SBE) or clinical breast exams (CBE), because cancers detected only through palpation are usually more advanced and therefore more threatening to the patient's health.
The Sentinel BreastScan does not replace mammography or ultrasound, nor is it intended to stand alone as a single test that can determine overall breast health. It can greatly improve the efficacy of those technologies by drawing attention to areas standard mammograms might miss such as areas within dense breast tissue or by localizing areas to be further investigated using ultrasound or MR technology.
We also plan to expand the role of our infrared imaging technology, in accordance with our FDA 510k, "indications for use" and devote R&D resources to the detection of skin cancer. Skin cancer has no approved imaging modalities and is detected by visual observation by a dermatologist followed by subsequent biopsy of suspicious lesions. Our early research has shown the ability of our technology to detect certain invisible skin cancers.
About Computer Vision Systems Laboratories
Computer Vision System Laboratories Corp is currently traded on the OTC BB and OTCQB under the symbol CVSL. Computer Vision Systems Laboratories Corp, formerly Cardio Vascular Medical Device Corp. is a development-stage company. Computer Vision Systems Laboratories has obtained the worldwide exclusive license for the FDA cleared Sentinel BreastScan which focuses on early detection of breast cancer. Additionally, the company is focused on licensing, partnering, manufacturing and / or distributing our patented breakthrough maneuverable-coiled guidewire. CVSL will seek strategic partners in the industry with which it will promote its guidewire product. Potential partners include St. Jude Medical, Cordis, a Johnson and Johnson company, Boston Scientific, Coviden, Vascular Solutions.
Parties interested in discussing the guidewire, Sentinel BreastScan, or investment opportunities may contact the CEO.